HDIAC Webinar - Biostasis
Friday, December 18, 2020

12:00 PM - 1:00 PM (Eastern Time)
Show in My Timezone
This webinar will provide an overview of the Defense Advanced Research Project Agency’s (DARPA) Biostasis program. The Biostasis program aims to extend the time for lifesaving medical treatment, often referred to as “the Golden Hour,” following traumatic injury or acute infection, thus increasing survivability for military personnel operating in far-forward conditions with limited access to medical professionals or trauma centers. To do so, Biostasis is developing novel chemical biology approaches that reversibly and controllably slow biological systems without cold-chain to stabilize and protect their functional capacity until medical intervention is possible.

Biostasis is investigating novel applications of polymer chemistry, protein engineering, and deep cell activity monitoring to alter the time course of pathological processes associated with tissue damage and infection to delay the onset of irreversible damage. Researchers are investigating approaches that are not dependent upon reducing temperature and that scale from preservation of simple biological therapeutics such as antibodies and enzymes to whole cells and tissues.

The program seeks to generate proof-of-concept, benchtop technologies and experimentally validate them in simple biological systems. DARPA will work with federal health and regulatory agencies as the program advances to develop a pathway for potential, future human medical use of successful Biostasis technologies. By the end of the program, DARPA hopes to have multiple tools for reducing the risk of permanent damage or death following acute injury or infection. Biostasis technologies could also extend the shelf-life of temperature-sensitive therapeutics, such as blood products, enzyme preparations, and drugs.

Presenter: Dr. Tristan McClure-Begley
Dr. Tristan McClure-Begley joined the Defense Advanced Research Project Agency (DARPA) as a Program Manager in October 2017.  His scientific pursuits at the agency involve novel chemical biology approaches to treating disease and injury, and developing methods to accelerate and protect learning and executive functions.

Dr. McClure-Begley came to DARPA from the University of Colorado, Boulder, where he was a Research Assistant Professor in the Department of Molecular, Cellular, and Developmental Biology. His academic studies focused on molecular mechanisms of perturbations to complex biological systems, particularly drugs of abuse, toxins, and neurodevelopmental disorders.  Prior to his faculty appointment at Colorado, Dr. McClure-Begley was a postdoctoral fellow in the Department of Psychiatry at the Yale University School of Medicine, and an alumnus of the Yale/NIDA Neuroproteomics Center.  He received his Doctor of Philosophy in Integrative Physiology and a Graduate Certificate in Behavioral Genetics from the University of Colorado, Boulder.
Please fill in the following fields to register for this meeting:
*
*
*
*
*
*
*
How did you hear about this webinar?
*
Would you like to be sent email notifying you about future HDIAC training resources?
Your e-mail address and personal information are confidential and will not be sold or rented.